PubRank

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

PubWeight™: 1.67‹?› | Rank: Top 3%

🔗 View Article (PMID 26424549)

Published in Lancet HIV on February 17, 2015

Authors

Chad J Achenbach1, Lambert Assoumou2, Steven G Deeks3, Timothy J Wilkin4, Baiba Berzins5, Joseph P Casazza6, Sidonie Lambert-Niclot7, Richard A Koup6, Dominique Costagliola2, Vincent Calvez7, Christine Katlama8, Brigitte Autran9, Robert L Murphy5, EraMune 02 study team

Author Affiliations

1: Center for Global Health and Division of Infectious Diseases, Northwestern University, Chicago, IL, USA. Electronic address: c-achenbach@northwestern.edu.
2: INSERM, UMRS 943, Paris, France; UPMC University of Paris 06, UMRS 943, Paris, France.
3: HIV/AIDS Division, San Francisco General Hospital and University of California San Francisco, San Francisco, CA, USA.
4: Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA.
5: Center for Global Health and Division of Infectious Diseases, Northwestern University, Chicago, IL, USA.
6: Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
7: INSERM, UMRS 943, Paris, France; UPMC University of Paris 06, UMRS 943, Paris, France; Department of Virology, AP-HP Pitié-Salpêtrière Hospital, Paris, France.
8: INSERM, UMRS 943, Paris, France; UPMC University of Paris 06, UMRS 943, Paris, France; Department of Infectious Diseases, AP-HP Pitié-Salpêtrière Hospital, Paris, France.
9: INSERM, UMRS 943, Paris, France; UPMC University of Paris 06, UMRS 943, Paris, France; Department of Immunology, AP-HP Pitié-Salpêtrière Hospital, Paris, France.

Associated clinical trials:

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir (EraMune02) | NCT00976404

Articles citing this ↘

Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc (2015) 0.78

IAS Towards an HIV Cure Symposium: people focused, science driven: 18-19 July 2015, Vancouver, Canada. J Virus Erad (2015) 0.78

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc (2017) 0.76

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology (2016) 0.76

Trying to cure HIV with immunotherapy: not so simple. Lancet HIV (2015) 0.75

Recent Advances in Lentiviral Vaccines for HIV-1 Infection. Front Immunol (2016) 0.75

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One (2016) 0.75